ライフサイエンスコーパス: differentiation antigen

1 ase (PAcP) is a prostate epithelium-specific differentiation antigen.

2 nduced expression of GpIIb, a megakaryocytic differentiation antigen.

3 cell resistance in part owing to the loss of differentiation antigens.

4 TSC1 or TSC2 gene function express melanoma differentiation antigens.

5 endocrine status, hypoxia, and oncofetal and differentiation antigens.

6 otic expression plasmids encoding melanocyte differentiation antigens.

7 lass I-restricted epitopes of two melanocyte differentiation antigens.

8 CD8+ T cell precursors specific for melanoma differentiation antigens.

9 s, albeit with a loss of tolerance to normal differentiation antigens.

10 tumor antigens are normal, nonmutated tissue differentiation antigens.

11 ns are nonmutated, poorly immunogenic tissue differentiation antigens.

12 and as a ligand for the CD21 and CD11b/CD11c differentiation antigens.

13 and gp75, are well-characterized melanocyte differentiation antigens.

14 clonal antibodies directed against leukocyte differentiation antigens.

15 Thymocyte differentiation antigen 1 (Thy1) was identified as a spe

16 , CD45, Lys76, Ly(-6c) and Ly(6c), thymocyte differentiation antigen 1, and discoidin domain receptor

17 ed to expand the marrow immature granulocyte differentiation antigen-1 cell pool and demonstrated few

18 y, recovery of the marrow mature granulocyte differentiation antigen-1 cell population after E. coli

19 n, and expansion the of immature granulocyte differentiation antigen-1 precursor cell population.

20 antigen-1 was induced in sorted granulocyte differentiation antigen-1, stem cell antigen-1' cells by

21 inhibited by an antibody against cluster of differentiation antigen 14 (CD14), an adhesion molecule

22 sulting in the down-regulation of cluster of differentiation antigen 4 (CD4) and major histocompatibi

23 ic acid-inducible gene-I (RIG-I) or melanoma differentiation antigen 5 and suppressed the downstream

24 n the intracellular adapter molecule myeloid differentiation antigen 88 (MyD88), which is required fo

25 ce deficient in the adaptor molecule myeloid differentiation antigen 88 (MyD88), which is required no

26 immunization of mice against the melanocyte differentiation antigen, a tyrosinase-related protein (T

27 directed against overexpressed self-derived differentiation antigens after a nonmyeloablative condit

28 ese antigens are mainly melanoma/ melanocyte differentiation antigens, although mutated intracellular

29 The role of CD4 on immature MK as a differentiation antigen and/or receptor for the human im

30 Many of these antigens are non-mutated differentiation antigens and are expressed by virtually

31 other fusion oncoproteins, myeloid-specific differentiation antigens and minor histocompatibility an

32 Differentiation antigens are prototypes of these self an

33 Self-antigens, in the form of differentiation antigens, are commonly recognized by the

34 roach was demonstrated using viral and self-(differentiation) antigens as models.

35 e refractory also to T cells recognizing non-differentiation antigens, as well as to BRAF + MEK inhib

36 responses, depending on the stage of B cell differentiation, antigen binding affinity, and duration

37 The murine B-lymphocyte differentiation antigen BP-1/6C3 has been identified as

38 ids encoding xenogeneic orthologues of tumor differentiation antigens can break immune ignorance and

39 inations against cancer have mainly targeted differentiation antigens, cancer-testis antigens, and ov

40 al-derived factor (PEDF), and serum monocyte differentiation antigen (CD-14) to predict whether a giv

41 er biomarker panel, including serum monocyte differentiation antigen (CD-14), ETS-related gene protei

42 single cells expressing the mature leukocyte differentiation antigen CD11b can also incorporate the t

43 or for IgG (Fc gamma RI/CD64) and the B-cell differentiation antigens CD19 and CD37.

44 -bound peptides from two leukemia-associated differentiation antigens; CD20 and the previously undesc

45 4.14.5; DPP IV), also known as the leukocyte differentiation antigen CD26 when found as an extracellu

46 cted against the cell surface myelomonocytic differentiation antigen CD33.

47 aries similar to those observed in the human differentiation antigen CD69.

48 immunoblastic lymphomas, with loss of B-cell differentiation antigens, clonal immunoglobulin heavy ch

49 CD14 is a monocyte differentiation antigen expressed by myeloid-derived cel

50 antigen receptor (CAR) specific for CD19, a differentiation antigen expressed in B cells and B linea

51 Nonmutated tissue differentiation antigens expressed by tumors are attract

52 er recombinant DNA vaccines targeting tissue differentiation antigens expressed by tumors.

53 nt and synthetic vaccines that target tissue differentiation antigens expressed by tumors.

54 Analysis of cytokine and differentiation antigen expression in human natural kill

55 CD8(+) T-cell responses against the melanoma differentiation antigens gp100 and tyrosinase-related pr

56 ce immune responses to five mouse melanocyte differentiation antigens, gp100, MART-1, tyrosinase, and

57 vity is essential for recruitment of myeloid differentiation antigen (Gr-1)-positive BMDCs, whereas V

58 oclonal antibodies that target hematopoietic differentiation antigens have been developed to treat he

59 in the expression of the cortical thymocyte differentiation antigen HTA 1 were derived from the T-ce

60 0% stained positively for the ED2 macrophage differentiation antigen, identifying them as perivascula

61 m untreated patients and increases monocytic differentiation antigens in some.

62 NI-1 cells expressed several MC differentiation antigens, including tryptase, Kit, and a

63 Immunohistochemical expression of melanocyte differentiation antigens, including tyrosinase-related-p

64 CD73, originally defined as a lymphocyte differentiation antigen, is thought to function as a cos

65 gnated Mndal (for MNDA-like, myeloid nuclear differentiation antigen-like), was absent in the suscept

66 Vaccine strategies targeting tissue differentiation antigens may be valuable in cancers aris

67 leads to increased expression of melanocyte differentiation antigens (MDA).

68 r/testis antigen, NY-ESO-1, and the melanoma differentiation antigen, Melan-A by human DC subsets.

69 s led to the recognition of a new melanocyte differentiation antigen, Melan-A(MART-1).

70 rent solid tumors known to express the tumor-differentiation antigen mesothelin.

71 e CCS/MSP included those encoding melanocyte differentiation antigens, MITF, SOX10, ERBB3, and FGFR1.

72 Reduced levels of human myeloid nuclear differentiation antigen (MNDA) gene transcripts have bee

73 that the PYHIN protein myeloid cell nuclear differentiation antigen (MNDA) is required for IFNalpha

74 s, including gp100 and TRP1 (melanoma tissue differentiation antigens), NY-ESO-1 (cancer/testis antig

75 A recently described breast tissue differentiation antigen, NY-BR-1, is expressed in >80% b

76 Cells expressing differentiation antigens of mature NK cells (CD56, CD16,

77 w melanoma-associated antigens that is not a differentiation antigen or a mutated protein.

78 and stromal cells and, subsequently, myeloid differentiation antigen-positive (Gr-1(+)) myeloid cell

79 oid dendritic cells and myeloid cell nuclear differentiation antigen-positive neutrophil precursors.

80 additional presence of myeloid cell nuclear differentiation antigen-positive precursor neutrophils.

81 TCR, CD3, and CD4, but little or no Thy-1, a differentiation antigen present on the great majority of

82 Mesothelin is a differentiation antigen present on the surface of ovaria

83 erse processes including cell-cycle control, differentiation, antigen presentation, and the stress re

84 le tumor types-transcriptional regulation of differentiation, antigen receptor signaling, tyrosine ki

85 inase family proteins are well characterized differentiation antigens recognized by antibodies and T

86 ogically normal intestine but also expressed differentiation antigens required for normal lymphoid ho

87 based vaccine vector expressing a melanocyte differentiation antigen resulted in T cell-dependent lon

88 only to one other known protein, the T cell differentiation antigen Rt6.

89 n this study, we expressed an anti-thymocyte differentiation antigen-scFv (Thy1-scFv) as a fusion pro

90 mmunotherapy to break tolerance against self-differentiation antigens shared by tumors.

91 ose (patient-derived) melanoma cell lines to differentiation antigen-specific cytotoxic T cells and o

92 Mesothelin is a tumor differentiation antigen that is highly expressed in many

93 trategy to search the dbEST database to find differentiation antigens that are expressed by cancers a

94 Examination of cell differentiation antigens that are up-regulated in FR(+)

95 active immunization against a relevant tumor differentiation antigen, the brown locus protein gp75.

96 , in variable proportions, all other NK cell differentiation antigens; the second subset expressed on

97 -primed memory T cells recognized melanocyte differentiation antigens TRP-2/DCT and gp100 and persist

98 Like other melamona differentiation antigens, TRP-2 was only expressed in me

99 isting of residues 180-188 of the melanocyte differentiation antigen tyrosinase-related protein (TRP)

100 tricted CD4+ TCR specific for the melanocyte differentiation antigen tyrosinase-related protein 1 (Ty

101 monoclonal antibody TA99 targeting melanoma differentiation antigen tyrosinase-related protein-1 (Ty

102 investigate immune responses to a melanocyte differentiation antigen, tyrosinase-related protein 1 (o

103 class II-restricted processing of melanocyte differentiation antigen, tyrosinase-related protein 1 (T

104 In this paper we identify a normal tissue differentiation antigen, tyrosinase-related protein 2 (T

105 Two proteins (caldesmon and myeloid nuclear differentiation antigen) were only weakly expressed in l

106 odel of tolerance maintained to a melanocyte differentiation antigen where tolerance can be broken by

107 Increased expression of PSMA, a differentiation antigen with folate hydrolase activity,

108 Targeting the CD33 differentiation antigen with gemtuzumab ozogamicin was t